Orthocell Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Paul Anderson

Chief executive officer

AU$621.6k

Total compensation

CEO salary percentage	70.8%
CEO tenure	18.7yrs
CEO ownership	3.0%
Management average tenure	1.8yrs
Board average tenure	6.7yrs

Recent management updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Recent updates

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Sep 09

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

CEO Compensation Analysis

How has Paul Anderson's remuneration changed compared to Orthocell's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$622k	AU$440k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$7m
Jun 30 2023	AU$651k	AU$420k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$531k	AU$380k	-AU$9m
Mar 31 2022	n/a	n/a	-AU$9m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$9m
Jun 30 2021	AU$1m	AU$375k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$9m
Dec 31 2020	n/a	n/a	-AU$8m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$578k	AU$370k	-AU$6m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$7m
Sep 30 2019	n/a	n/a	-AU$6m
Jun 30 2019	AU$582k	AU$365k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$6m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$597k	AU$365k	-AU$6m

Compensation vs Market: Paul's total compensation ($USD404.14K) is above average for companies of similar size in the Australian market ($USD298.50K).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Anderson (58 yo)

18.7yrs

Tenure

AU$621,574

Compensation

Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Anderson	CEO, MD & Executive Director	no data	AU$621.57k	3% A$ 4.5m
Nicole Telford	Chief Financial Officer	no data	no data	2.64% A$ 3.9m
Alex McHenry	Chief Operating Officer	5.8yrs	no data	no data
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	no data	1.42% A$ 2.1m
Tony Macintyre	Chief Technical Operations Officer	1.8yrs	no data	no data
Vik Malik	Chief Commercial Officer	less than a year	no data	no data
Peter Webse	Company Secretary	1.7yrs	no data	no data

1.8yrs

Average Tenure

Experienced Management: OCC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Anderson	CEO, MD & Executive Director	18.7yrs	AU$621.57k	3% A$ 4.5m
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	no data	1.42% A$ 2.1m
Fiona Wood	Independent Non-Executive Director	less than a year	AU$448.66k	0.0068% A$ 10.1k
Samuel Asculai	Chairman of Medical & Scientific Advisory Board	no data	no data	no data
Ray Crowe	Member of Medical & Scientific Advisory Board	no data	no data	no data
Gregory Janes	Member of Medical & Scientific Advisory Board	no data	no data	no data
David Wood	Member of Medical & Scientific Advisory Board	no data	no data	no data
Alan Wang	Member of Medical & Scientific Advisory Board	no data	no data	no data
John Van Der Wielen	Independent Non-Executive Chairman	1.4yrs	AU$150.00k	0.14% A$ 203.1k
Rocky Tuan	Member of Medical & Scientific Advisory Board	8.7yrs	no data	no data
Massimo Simion	Member of Medical & Scientific Advisory Board	6.7yrs	no data	no data
Giuseppe Luongo	Member of Medical & Scientific Advisory Board	6.7yrs	no data	no data

6.7yrs

Average Tenure

Experienced Board: OCC's board of directors are considered experienced (6.7 years average tenure).

Orthocell Management

Management criteria checks 2/4

Key information

Recent management updates

CEO, MD & Executive Director exercised options to buy AU$190k worth of stock.

Orthocell Limited, Annual General Meeting, Nov 29, 2024

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 17 million.

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 17 million.

CEO, MD & Executive Director exercised options to buy AU$190k worth of stock.

Orthocell Limited, Annual General Meeting, Nov 29, 2024

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Full year 2024 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2023)

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure